PET monitoring of therapy response in head and neck squamous cell carcinoma

Journal of Nuclear Medicine

Volumn 50, Issue SUPPL. 1, 2009, Pages

  Schöder, Heiko ^a   Fury, Matthew ^a   Lee, Nancy ^a   Kraus, Dennis ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Head and neck cancer; Oncology; PET; PET CT; Treatment response

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NV 1023; ONCOLYTIC HERPES VIRUS; ONYX 015; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALGORITHM; AMINO ACID TRANSPORT; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER SIZE; DRUG UPTAKE; FALSE POSITIVE RESULT; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; LARYNGECTOMY; LARYNX CANCER; NONHUMAN; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RADIOISOTOPE DISTRIBUTION; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 66149148732     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.057208     Document Type: Review

References (136)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
3. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952. (Pubitemid 38580197)
4. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843-850.
5. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098. (Pubitemid 37464533)
6. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76. (Pubitemid 41095116)
7. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
8. McHam SA, Adelstein DJ, Rybicki LA, et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck. 2003;25:791-798.
9. Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58:1418-1423. (Pubitemid 38438302)
10. Frank DK, Hu KS, Culliney BE, et al. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. Laryngoscope. 2005;115:1015-1020. (Pubitemid 40776993)
11. Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combinedmodality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004;26:447-455. (Pubitemid 38569204)
12. Mendenhall WM, Million RR, Cassisi NJ. Squamous cell carcinoma of the head and neck treated with radiation therapy: the role of neck dissection for clinically positive neck nodes. Int J Radiat Oncol Biol Phys. 1986;12:733-740. (Pubitemid 16033470)
13. Boyd TS, Harari PM, Tannehill SP, et al. Planned postradiotherapy neck dissection in patients with advanced head and neck cancer. Head Neck. 1998;20:132-137. (Pubitemid 28106225)
14. Lee HJ, Zelefsky MJ, Kraus DH, et al. Long-term regional control after radiation therapy and neck dissection for base of tongue carcinoma. Int J Radiat Oncol Biol Phys. 1997;38:995-1000. (Pubitemid 27353678)
15. Lavertu P, Adelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck. 1997;19:559-566. (Pubitemid 27407309)
16. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multiinstitutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:281-288.
17. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer: disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009;73:399-409.
18. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25:4800-4805. (Pubitemid 350086484)
19. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:731-740. (Pubitemid 46818729)
20. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
21. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149-153.
22. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006;5:1779-1787. (Pubitemid 44435320)
23. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
24. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62. (Pubitemid 40093472)
25. Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:1008-1012.
26. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008.
27. Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest. 1996;98:2507-2511.
28. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007;26:281-290.
29. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007;67:563-572. (Pubitemid 46192193)
30. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res. 2007;67:7646-7653. (Pubitemid 47281357)
31. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007;13:5670-5674. (Pubitemid 47583891)
32. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273-286.
33. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008;35:274-285.
34. Shemirani B, Crowe DL. Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol. 2000;36:61-66.
35. Riedel F, Gotte K, Schwalb J, Wirtz H, Bergler W, Hormann K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol. 2000;257:332-336. (Pubitemid 30612326)
36. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:624-630. (Pubitemid 41558557)
37. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18:2046-2052. (Pubitemid 30324357)
38. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434-1440. (Pubitemid 40315223)
39. ClinicalTrials.gov. Cisplatin, bevacizumab, and intensity-modulated radiation therapy in treating patients with stage III or stage IV head and neck cancer. ClinicalTrials.gov identifier NCT00423930. Available at: http://clinicaltrials. gov/ct2/show/NCT00423930?term= head+and+neck+cancer&recr=Open& rank=26. Accessed March 27, 2009.
40. Fury MG, Zahalsky A, Wong R, et al. A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs. 2007;25:165-172. (Pubitemid 46020876)
41. Bozec A, Gros FX, Penault-Llorca F, et al. Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer. 2008;44:1922-1930.
42. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer. 2007;97:65-72. (Pubitemid 47012080)
43. Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer. 2008;99:93-99.
44. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374-3378. (Pubitemid 29334495)
45. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-3584. (Pubitemid 23229640)
46. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356. (Pubitemid 36025259)
47. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer. 2005;41:453-460. (Pubitemid 40187218)
48. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24:4170-4176. (Pubitemid 46622295)
49. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005;11:5856-5862. (Pubitemid 41170313)
50. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25:2164-2170. (Pubitemid 46954638)
51. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2659-2665. (Pubitemid 46622087)
52. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799. (Pubitemid 46606324)
53. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-8654. (Pubitemid 46211507)
54. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2866-2872. (Pubitemid 46630587)
55. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-5577. (Pubitemid 46300151)
56. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5578-5587. (Pubitemid 46300152)
57. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177. (Pubitemid 46954639)
58. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
59. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
60. ClinicalTrials.gov. TPF plus cisplatin and radiotherapy vs TPF plus cetuximab and radiotherapy to treat head and neck cancer. ClinicalTrials.gov identifier NCT00716391. Available at: http://clinicaltrials.gov/ct2/show/ NCT00716391? term=head+and+neck+cancer&recr=Open&rank=10. Accessed March 27, 2009.
61. ClinicalTrials.gov. Radiation therapy and cisplatin with or without cetuximab in treating patients with stage III or stage IV head and neck cancer. ClinicalTrials.gov identifier NCT00265941. Available at: http://clinicaltrials. gov/ct2/show/NCT00265941?term=head+and+neck+cancer&recr=Open& rank=48. Accessed March 27, 2009.
62. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85. (Pubitemid 41095117)
63. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11:8418-8424. (Pubitemid 41746956)
64. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007;25:2178-2183. (Pubitemid 46954640)
65. 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004;26:890-896.
66. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys. 2004;60:1410-1418. (Pubitemid 39610495)
67. 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532-540.
68. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315-1322. (Pubitemid 44425218)
69. Gourin CG, Williams HT, Seabolt WN, Herdman AV, Howington JW, Terris DJ. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope. 2006;116:705-710. (Pubitemid 44318024)
70. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PETCT. Laryngoscope. 2007;117:2129-2134.
71. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65-72. (Pubitemid 38375411)
72. Branstetter BF IV, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005;235:580-586.
73. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:105-109. (Pubitemid 38095439)
74. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck. 2005;27:175-181. (Pubitemid 40315765)
75. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991-999. (Pubitemid 41505274)
76. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 2000;110:1493-1497.
77. Greven KM, Williams DW III, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942-946. (Pubitemid 32977536)
78. Forrester HB, Albright N, Ling CC, Dewey WC. Computerized video timelapse analysis of apoptosis of REC:Myc cells x-irradiated in different phases of the cell cycle. Radiat Res. 2000;154:625-639.
79. Luce A, Courtin A, Levalois C, et al. Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis. 2009;30:432-439.
80. Dornfeld K, Hopkins S, Simmons J, et al. Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:386-392.
81. Connell CA, Corry J, Milner AD, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29:986-995.
82. 18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173-1179.
83. Sanguineti G, Corvo R, Benasso M, et al. Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer. Head Neck. 1999;21:223-228. (Pubitemid 29144582)
84. Velazquez RA, McGuff HS, Sycamore D, Miller FR. The role of computed tomographic scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Arch Otolaryngol Head Neck Surg. 2004;130:74-77. (Pubitemid 38095433)
85. Radiation Therapy Oncology Group (RTOG 0522): A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin and cetuximab (C225) (followed by surgery for selected patients) for stage III and IV head and neck carcinomas. Available at: http://www.rtog.org/members/protocols/0522/0522.pdf. Accessed March 27, 2009.
86. 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007;48(suppl 1):58S-67S.
87. Robbins KT, Shannon K, Vieira F. Superselective neck dissection after chemoradiation: feasibility based on clinical and pathologic comparisons. Arch Otolaryngol Head Neck Surg. 2007;133:486-489. (Pubitemid 46799786)
88. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):27-37. (Pubitemid 44139191)
89. Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am. 2008;46:225-241.
90. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135. (Pubitemid 34111509)
91. ClinicalTrials.gov. Docetaxel based chemotherapy plus or minus induction chemotherapy to decrease events in head and neck cancer (DeCIDE). ClinicalTrials.gov identifier NCT00117572. Available at: http://clinicaltrials. gov/ct2/show/NCT00117572?term5DECIDE&rank54. Accessed March 27, 2009.
92. ClinicalTrials.gov. TPF induction with concomitant chemoradiation to treat patients with head and neck cancer (Condor). ClinicalTrials.gov identifier NCT00774319. Available at: http://clinicaltrials.gov/ct2/show/NCT00774319? term=head+and+neck+cancer&recr=Open&rank=42. Accessed March 27, 2009.
93. ClinicalTrials.gov. Induction chemotherapy prior to radio-immunotherapy in head and neck cancer stage III/IV: a methodical trial (ASOG-HNO1). ClinicalTrials.gov identifier NCT00502463. Available at: http://clinicaltrials. gov/ct2/show/NCT00502463. Accessed March 27, 2009.
94. Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:322-329.
95. Heron DE, Andrade RS, Beriwal S, Smith RP. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol. 2008;31:352-362.
96. 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med. 2003;44:1432-1434.
97. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
98. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy- 3′fluorothymidine uptake. Nucl Med Biol. 2004;31:419-423. (Pubitemid 38490741)
99. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
100. 18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol. 2007;9:340-347.
101. Atkinson DM, Clarke MJ, Mladek AC, et al. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck. 2008;30:790-799.
102. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735. (Pubitemid 47604972)
103. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285-289 (Pubitemid 27318643)
104. Becker A, Hansgen G, Bloching M, Weigel C, Lautenschlager C, Dunst J. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys. 1998;42:35-41. (Pubitemid 28435593)
105. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77:18-24. (Pubitemid 41503384)
106. Barendsen GW, Koot CJ, Van Kersen GR, Bewley DK, Field SB, Parnell CJ. The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int J Radiat Biol Relat Stud Phys Chem Med. 1966;10:317-327.
107. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 1996;6:3-9. (Pubitemid 26029370)
108. Gabalski EC, Adam M, Pinto H, Brown JM, Bloch DA, Terris DJ. Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers. Laryngoscope. 1998;108:1856-1860. (Pubitemid 28559672)
109. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699-757.
110. Schoder H, Ong SC. Fundamentals of molecular imaging: rationale and applications with relevance for radiation oncology. Semin Nucl Med. 2008;38:119-128.
111. Rosenberg A, Knox S. Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys. 2006;64:343-354. (Pubitemid 43083418)
112. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:769-778. (Pubitemid 34158740)
113. Rischin D, Peters L, O'Sullivan B, et al. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2008;26:(suppl):LBA6008.
114. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104.
115. 18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. February 7, 2009 [Epub ahead of print].
116. Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol. 2007;25:2184-2190. (Pubitemid 46954641)
117. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340-3346. (Pubitemid 46638887)
118. Bastholt L, Specht L, Jensen K, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax- EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2007;85:24-28. (Pubitemid 47562580)
119. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659-5667. (Pubitemid 44629592)
120. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850-858.
121. Mishani E, Abourbeh G, Jacobson O, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem. 2005;48:5337-5348. (Pubitemid 41113919)
122. 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol. 2006;8:262-277.
123. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049.
124. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
125. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
126. Clezardin P. Recent insights into the role of integrins in cancer metastasis. Cell Mol Life Sci. 1998;54:541-548. (Pubitemid 28325627)
127. 18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616.
128. Nemunaitis J, O'Brien J. Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors. Expert Opin Biol Ther. 2002;2:177-185.
129. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000;60:6359-6366.
130. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther. 2002;13:1213-1223. (Pubitemid 34746701)
131. Gil Z, Kelly KJ, Brader P, Shah JP, Fong Y, Wong RJ. Utility of a herpes oncolytic virus for the detection of neural invasion by cancer. Neoplasia. 2008;10:347-353.
132. 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004;26:890-896.
133. Ware RE, Matthews JP, Hicks RJ, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck. 2004;26:1008-1017. (Pubitemid 39601219)
134. Brkovich VS, Miller FR, Karnad AB, Hussey DH, McGuff HS, Otto RA. The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Laryngoscope. 2006;116:855-858. (Pubitemid 44317978)
135. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg. 2007;133:435-440. (Pubitemid 46799778)
136. 18F]-fluorodeoxyglucose positron emission tomography imaging in management of head and neck cancer: a long term outcome report. Int J Radiat Oncol Biol Phys. In press.